Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2024-204878

Published: 2024

Journal Articles

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Kristin Rathje, Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2023-185991

Published: 2023

Journal Articles

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 896.

https://doi.org/10.1182/blood-2023-179489

Published: 2023

Journal Articles

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Nico Gagelmann, Gabriela S. Hobbs, Edoardo Campodonico, Polona Novak, Vaneuza Funke, Vanderson Rocha, Nelson Hamerschlak, Thomas Schroeder, Christina Rautenberg, Linette Bosques, Raffaella Greco, Artur Schneider, Grzegorz Helbig, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2023-191300

Published: 2023

Journal Articles

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Nico Gagelmann, Anita Badbaran, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger

Blood (2023) 141 (23): 2901–2911.

https://doi.org/10.1182/blood.2023019630

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax and Hypomethylating Agents Followed By Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Christina Rautenberg, Anja Ragette, Jennifer Kaivers, Nina Neuendorff, Maher Hanoun, Hans Christian Reinhardt, Thomas Schroeder

Blood (2022) 140 (Supplement 1): 12943–12944.

https://doi.org/10.1182/blood-2022-169893

Published: 2022

Journal Articles

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Nico Gagelmann, Anita Badbaran, Rachel Beth Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Arnold Ganser, Christina Rautenberg, Bruno Cassinat, Felicitas R Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 828–829.

https://doi.org/10.1182/blood-2022-158900

Published: 2022

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe

Blood (2021) 138 (Supplement 1): 411.

https://doi.org/10.1182/blood-2021-153282

Published: 2021

Journal Articles

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, PhD, Olivier Nibourel, Friedrich Stoelzel, MD, Christina Rautenberg, MD, Heiko Becker, MD, Aleksandar Radujkovic, MD, Michael Koldehoff, Prof, MD PhD, Maximilian Christopeit, PhD, Peter Dreger, Jürgen Finke, MD, Guido Kobbe, MD, Uwe Platzbecker, Marie Robin, MD, Dietrich W. Beelen, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 1713.

https://doi.org/10.1182/blood-2019-121969

Published: 2019

Journal Articles

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Blood (2019) 134 (Supplement_1): 4563.

https://doi.org/10.1182/blood-2019-125087

Published: 2019

Journal Articles

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Annika Kasprzak, Kathrin Nachtkamp, MD, Mustafa Kondakci, MD, Thomas Schroeder, MD, Guido Kobbe, MD, Andrea Kündgen, MD, Jennifer Kaivers, MD, Christina Rautenberg, MD, Rainer Haas, MD, Norbert Gattermann, MD, Nicolas Bonadies, MD, Ulrich Germing, MD

Blood (2019) 134 (Supplement_1): 4250.

https://doi.org/10.1182/blood-2019-124512

Published: 2019

Journal Articles

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

Christina Rautenberg, MD, Stefanie Stepanow, Michael Lauseker, Ulrich Germing, MD, Paul Jäger, Stefanie Geyh, Esther Schuler, Karl Köhrer, Norbert Gattermann, MD, Rainer Haas, MD, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2019) 134 (Supplement_1): 4612.

https://doi.org/10.1182/blood-2019-126565

Published: 2019

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Thomas Michael Schroeder, MD PhD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Christoph Groth, MD, Christoph Scheid, MD, Udo Holtick, MD PhD, Stefan A Klein, MD, Dietrich W. Beelen, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, MD, Guido Kobbe

Blood (2018) 132 (Supplement 1): 703.

https://doi.org/10.1182/blood-2018-99-113776

Published: 2018

Journal Articles

WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate"

Christina Rautenberg, MD, Sabrina Pechtel, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, MD, Guido Kobbe, Thomas Michael Schroeder, MD PhD

Blood (2018) 132 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2018-99-113524

Published: 2018

Journal Articles

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Christina Rautenberg, MD, Beate Betz, Dagmar Wieczorek, Barbara Hildebrandt, Kathrin Nachtkamp, MD, Esther Schuler, Norbert Gattermann, MD, Guido Kobbe, MD, Rainer Haas, MD, Thomas Schroeder, MD

Blood (2017) 130 (Supplement 1): 2005.

https://doi.org/10.1182/blood.V130.Suppl_1.2005.2005

Published: 2017

Journal Articles

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Thomas Schroeder, MD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Stefan Klein, MD, Christof Scheid, MD, Dietrich W Beelen, MD PhD, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, Guido Kobbe, MD

Blood (2017) 130 (Supplement 1): 4521.

https://doi.org/10.1182/blood.V130.Suppl_1.4521.4521

Published: 2017

Journal Articles

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Thomas Schroeder, MD, Christina Rautenberg, MD, William Hermann Krüger, MD PhD, Uwe Platzbecker, MD, Gesine Bug, MD, Steinmann Juliane, Stefan A. Klein, MD, Olaf Hopfer, Kathrin Nachtkamp, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Pia Verena Schmidt, MD, Claudia Heyn, MD, Rainer Haas, MD, Ulrich Germing, Martin Bornhäuser, MD, Guido Kobbe, MD

Blood (2016) 128 (22): 3446.

https://doi.org/10.1182/blood.V128.22.3446.3446

Published: 2016

Journal Articles

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Christina Rautenberg, MD, Sabrina Pechtel, Barbara Hildebrandt, Beate Betz, Ariane Dienst, MD, Kathrin Nachtkamp, MD, Stefanie Geyh, Pia Verena Schmidt, MD, Claudia Heyn, MD, Mustafa Kondakci, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2016) 128 (22): 3447.

https://doi.org/10.1182/blood.V128.22.3447.3447

Published: 2016

NARROW

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies - a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Venetoclax and Hypomethylating Agents Followed By Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate"

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only